Patient-reported pain and other quality of life domains as prognostic factors for survival in a phase III clinical trial of patients with advanced breast cancer

Table 4 Prognostic Effect of BPI-SF and RSCL on Survival

HRQOL subscale variables ^a	n ^b	HR	95 % CI	p-value	HR	95 % CI	p-value
HRQOL subscale variables ^a		Univariate			Multivariate^c
BPI-SF – Pain Interference	282	1.07	1.02–1.12	0.0061	1.02	0.97–1.08	0.3931
BPI-SF – Worst Pain	279	1.07	1.03–1.12	0.0013	1.05	1.00–1.10	0.0342
RSCL – Activity Level	330	0.86	0.82–0.91	<0.0001	0.89	0.83–0.95	0.0004
RSCL – Physical Distress	333	0.88	0.81–0.97	0.0104	0.92	0.83–1.02	0.1053
RSCL – Psychological Distress	332	0.96	0.91–1.01	0.1025	0.98	0.92–1.03	0.3800
RSCL – HRQOL	324	0.91	0.87–0.96	0.0002	0.95	0.90–1.01	0.0810

BPI-SF Brief Pain Inventory-Short Form; CI confidence interval; HR hazard ratio; HRQOL health-related quality of life; KPS Karnofsky Performance Status; n number of patients with nonmissing values on a variable among randomized patients; RSCL Rotterdam Symptom Checklist
^aHRs for every 1-point increase in the BPI-SF and every 10-point increase in the RSCL subscales
^bIncludes 1 patient with missing KPS score and not included in Tables 2 and 3. This patient’s scores were as follows: BPI Pain Interference, 0; BPI Worst Pain, 0; RSCL Activity, 100; RSCL Physical, missing; RSCL Psychological, missing; RSCL HRQOL, 83.33
^cMultivariate Cox proportional hazards models were used to determine each HR in the presence of 11 demographic/clinical variables: age, race, KPS, estrogen receptor status, progesterone receptor status, presence of visceral disease, prior radiotherapy, prior hormonal treatment, menopausal status, basis for pathological diagnosis, and pathological diagnosis

ISSN: 1477-7525